Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant atezolizumab in urothelial cancer
2019-004628-39Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in transitional cell carcinoma (TCC), ureteral cancer, upper tract urothelial carcinoma (UTUC) and 1 more, sponsored by Queen Mary University of London. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)ureteral cancerupper tract urothelial carcinoma (UTUC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2019-004628-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004628-39.